| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a3e06b739fa9ae6a96b7ba808b9cd0a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5c57f85226a97eb8c16b3094fcb0d44f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-8128
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-974
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2337-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-75 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-56 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86 |
| filingDate |
1990-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1995-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8648482573d78df7934fb85afafd1c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6f19c9c86a1891f7f200561600e2f7a |
| publicationDate |
1995-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0420332-B1 |
| titleOfInvention |
Method for determining the endogenous thrombin potential of plasma and blood, and also a kit for use in said method |
| abstract |
A method for determining the endogenous thrombin potential (ETP). which shows how much and for what length of time thrombin has been active in a sample of clotting blood or plasma. The ETP can be used for determining the effectiveness of treatment with antithrombotics of any type. Said ETP determination comprises adding to said sample a thrombin substrate, an activator of thrombin formation, a preparation of proteaseinhibitor and if desired a pharmaceutical for analysis . The thrombin substrate is preferably selected to not completely consume the amount of thrombin generated in the sample, to have a rate of conversion of the substrate which is proportional to the amount of thrombin present and to have a measurable conversion product resulting from the conversion by thrombin. Determination of the amount of conversion product leads to determination of the ETP. The choice of activator determines whether the effect is measured on the intrinsic or extrinsic clotting system, making it possible to determine the effect of the pharmaceutical, which is being analysed, on various parts of the clotting mechanism. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7785820-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018234308-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7981622-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021019529-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7691641-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1983061-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1684071-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7893030-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-102007017906-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4239338-A1 |
| priorityDate |
1989-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |